For the Inventor, By the Inventor

Enter assignee name

Alameda, CA, United States of America

Avigen, Inc.

USPTO Granted Patents = 31

CIPO Patents = 1

EPO Patents = 4

Forward Citations = 1,062

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Peter C Colosi (14 out of 21 patents)

Gary J Kurtzman (12 out of 20 patents)

Gregory M Podsakoff (5 out of 12 patents)

4. Georges Natsoulis (4 out of 5 patents)

5. Paul D Kessler (3 out of 10 patents)

6. Barry J Byrne (3 out of 8 patents)

7. Kirk William Johnson (3 out of 36 patents)

8. Hideho Okada (2 out of 12 patents)

9. Federico C A Gaeta (2 out of 24 patents)

10. Hema S Sista (2 out of 5 patents)

11. Yero J Espinoza (2 out of 5 patents)

12. Matthew I Gross (2 out of 3 patents)

13. Xiaobing Qian (2 out of 3 patents)

14. Jun Yoshida (2 out of 3 patents)

15. Linda B Couto (2 out of 2 patents)

31 patents: Sort by Forward Citations

1. 7622256 - Method for selecting compounds that modulate MIF-induced expression of ICAM-1 and/or VCAM-1 (2009-11-24),

2. 7585875 - Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use (2009-09-08),

3. 7534806 - Method for treating neuropathic pain and associated syndromes (2009-05-19),

4. 7037713 - High-efficiency wild-type-free AAV helper functions (2006-05-02),

5. 6953575 - Methods of treating central nervous system disorders using viral vectors (2005-10-11),

6. 6897063 - Accessory functions for use in recombinant AAV virion production (2005-05-24),

7. 6764845 - Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith (2004-07-20),

8. 6759050 - Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith (2004-07-06),

9. 6593123 - Large-scale recombinant adeno-associated virus (rAAV) production and purification (2003-07-15),

10. 6531456 - Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors (2003-03-11),

11. 6482633 - Accessory functions for use in recombinant AAV virion production (2002-11-19),

12. 6416992 - Compositions and methods for producing recombinant adeno-associated virus (2002-07-09),

13. 6391858 - Methods for delivering DNA to the bloodstream using recombinant adeno-associated virus vectors (2002-05-21),

14. 6376237 - High-efficiency wild-type-free AAV helper functions (2002-04-23),

15. 6365403 - High-efficiency AAV helper functions (2002-04-02),

Avigen, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare genetic diseases. With a focus on targeting the central nervous system, Avigen's goal is to provide transformative treatments for patients and improve their quality of life. The company's scientists and researchers work diligently to uncover novel approaches to gene therapy, leveraging cutting-edge technologies and collaborations with leading academic institutions. Avigen is committed to delivering safe and effective therapies to patients in need, addressing the unmet medical needs in the field of genetic disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

31 Patents

#14 in Alameda, CA

#2,529 in California

#10,562 in US

#20,639 in the World

Alameda, CA, United States of America

Avigen, Inc.

Forward Citations = 1,062

30 inventors:

Peter C Colosi (14 out of 21 patents)

Gary J Kurtzman (12 out of 20 patents)

Gregory M Podsakoff (5 out of 12 patents)

4. Georges Natsoulis (4 out of 5 patents)

5. Paul D Kessler (3 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…